var data={"title":"Raltegravir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Raltegravir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/336310?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">see &quot;Raltegravir: Drug information&quot;</a> and <a href=\"topic.htm?path=raltegravir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Raltegravir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374882\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Isentress;</li>\n      <li>Isentress HD</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5937103\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Isentress;</li>\n      <li>Isentress HD</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6771674\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral, Integrase Inhibitor (Anti-HIV)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">HIV Agents (Anti-HIV Agents)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Integrase Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50713372\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection, treatment:</b> <b>Note:</b> Use in combination with other antiretroviral agents. Term neonate (&ge;37 weeks GA) and weighing &ge;2 kg: Oral suspension (10 mg/mL): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &le;7 days:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-based dosing: 1.5 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">2 to &lt;3 kg: 4 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">3 to &lt;4 kg: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">4 to &lt;5 kg: 7 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA 8 to 28 days:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-based dosing: 3 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">2 to &lt;3 kg: 8 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">3 to &lt;4 kg: 10 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">4 to &lt;5 kg: 15 mg twice daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6771726\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">see &quot;Raltegravir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioequivalent and are not substitutable on a mg/mg basis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 infection, treatment:</b> Oral: <b>Note:</b> Use in combination with other antiretroviral agents.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Oral suspension (10 mg/mL):</i> Infants and Children &lt;20 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-based dosing: 6 mg/kg/dose twice daily; maximum dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">3 to &lt;4 kg: 25 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">4 to &lt;6 kg: 30 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">6 to &lt;8 kg: 40 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">8 to &lt;11 kg: 60 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">11 to &lt;14 kg: 80 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">14 to &lt;20 kg: 100 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chewable tablets:</i> Children weighing &ge;11 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-based dosing: 6 mg/kg/dose twice daily; maximum dose: 300 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">11 to &lt;14 kg: 75 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">14 to &lt;20 kg: 100 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to &lt;28 kg: 150 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">28 to &lt;40 kg: 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;40 kg: 300 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Film-coated tablets:</i> For patients able to swallow a tablet whole:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Isentress: 400 mg tablets: Children and Adolescents &ge;25 kg: 400 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Isentress HD: 600 mg tablets: Children and Adolescents &ge;40 kg: 1,200 mg once daily. <b>Note: </b>Patients virologically suppressed on an initial regimen of raltegravir 400 mg twice daily may switch to 1,200 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 nonoccupational postexposure prophylaxis (nPEP)</b> (HHS [nPEP] 2016): <b>Note:</b> Initiate therapy within 72 hours of exposure and continue for 28 days; use in combination with other antiretroviral agents.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;2 years: Oral: <i>Oral suspension (10 mg/mL):</i> 6 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;2 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Chewable tablets:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">11 to &lt;14 kg: 75 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">14 to &lt;20 kg: 100 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to &lt;28 kg: 150 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">28 to &lt;40 kg: 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;40 kg: 300 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Film-coated tablet:</i> Isentress 400 mg tablet: Children &ge;6 years weighing &gt;25 kg who are able to swallow a tablet whole: 400 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: <i>Film-coated tablet:</i> Isentress 400 mg tablet: 400 mg twice daily for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for concomitant rifampin therapy:</b> Pediatric-specific dosing recommendations are lacking; in adult patients, dosing adjustment suggested</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>HIV infection, treatment:</b> Oral: <b>Note:</b> Raltegravir is a component of a recommended initial regimen with tenofovir plus emtricitabine (or lamivudine) or tenofovir alafenamide plus emtricitabine in ART-naive patients (HHS [adult] 2016); may also be used in combination with darunavir and ritonavir as part of a nucleoside-sparing regimen in ART-naive patients with HIV-1 viral load &lt;100,000 copies/mL and CD4 count &gt;200 cells/mm<sup>3</sup> (HHS [adult] 2016; Raffi 2014; Taiwo 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment-naive patients: </i>Film-coated tablet: 400 mg twice daily or 1,200 mg once daily (2 x 600 mg tablet). <b>Note:</b> Patients virologically suppressed on an initial regimen of raltegravir 400 mg twice daily may switch to 1,200 mg (2 x 600 mg tablet) once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment-experienced patients</i>: Film-coated tablet: 400 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for concomitant therapy:</b> Adults: Concomitant rifampin therapy: Raltegravir dose: Film-coated tablet: 800 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild, moderate, or severe impairment: No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Dose after dialysis on dialysis days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Film-coated tablet (400 mg formulation), chewable tablet, oral suspension: Infants, Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate hepatic impairment: No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Film-coated tablet (600 mg formulation): Pediatric patients &ge;40 kg and Adults: Use is not recommended (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374928\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isentress: 100 mg (1 ea, 60 ea) [contains polyethylene glycol; banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isentress: 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isentress HD: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isentress: 25 mg [contains aspartame, saccharin sodium; orange banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isentress: 100 mg [scored; contains aspartame, saccharin sodium; orange banana flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374884\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20326223\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chewable tablets: May be chewed or swallowed whole; 100 mg chewable tablet can be split in half.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Film-coated tablets: Must be swallowed whole.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Administer dose (at a concentration of 10 mg/mL) within 30 minutes of reconstitution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374908\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Film-coated and chewable tablets: Store in the original package; keep desiccant in the bottle to protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Store in the original container; do not open foil packet until ready for reconstitution and use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6771675\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of HIV-1 infection in combination with other antiretroviral agents (Isentress: FDA approved in pediatric patients weighing &ge;2 kg and adults; Isentress HD: FDA approved in pediatric patients weighing &ge;40 kg and adults). <b>Note:</b> HIV regimens consisting of <b>three</b> antiretroviral agents are strongly recommended. Has also been used for HIV-1 nonoccupational postexposure prophylaxis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708058\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374899\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal behavior (children and adolescents), abnormal dreams, depression (particularly in subjects with a preexisting history of psychiatric illness), dizziness, fatigue, headache, insomnia, nightmares, psychomotor agitation (children and adolescents), suicidal ideation, suicidal tendencies</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Allergic rash (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased serum glucose (more common with 126 to 250 mg/dL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, decreased appetite, diarrhea, dyspepsia, flatulence, gastritis, increased serum amylase, increased serum lipase, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Herpes genitalis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased hemoglobin, decrease in absolute neutrophil count, malignant neoplasm, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis, hyperbilirubinemia (incidence slightly higher with hepatitis B and/or C coinfection), increased serum alkaline phosphatase, increased serum ALT (incidence higher with hepatitis B and/or C coinfection), increased serum AST (incidence higher with hepatitis B and/or C coinfection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Herpes zoster</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase, myopathy, rhabdomyolysis, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine, nephrolithiasis, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anxiety, cerebellar ataxia, DRESS syndrome (Perry 2013), hepatic failure, immune reconstitution syndrome, paranoia, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374893\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to raltegravir or any other component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374894\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy: Grade 2 to 4 creatine kinase (CK) increases have been observed and myopathy and rhabdomyolysis have been reported; use caution in patients with a history of rhabdomyolysis, myopathy, or increased serum creatine kinase or who have risk factors for CK elevations and/or skeletal muscle abnormalities, including taking other drugs known to cause myopathy or rhabdomyolysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin and hypersensitivity reactions: Severe, life-threatening or fatal cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Hypersensitivity reactions (rash, constitutional symptoms, organ dysfunction) have also been reported. Discontinue immediately if a severe skin reaction or hypersensitivity symptoms develop. Monitor clinical status, including liver transaminases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chewable tablet: Contains phenylalanine; avoid or use with caution in patient with phenylketonuria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablets and oral suspension: Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioequivalent and are not substitutable on a mg/mg basis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Raltegravir plus darunavir/ritonavir should not be used in adolescent and adult HIV-1 patients with a pre-ART CD4 count &lt;200 cells/mm<sup>3</sup> and/or HIV RNA &gt;100,000 copies/mL (HHS [adult] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299978\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of UGT1A1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374903\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=89430&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: May decrease the serum concentration of Raltegravir. Management: Avoid the use of oral / enteral aluminum hydroxide with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Carbonate: May decrease the serum concentration of Raltegravir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Raltegravir. Management: Concurrent use of etravirine with once-daily raltegravir (Isentress HD) is not recommended. Concurrent use of other raltegravir products with etravirine does not require any dose change.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: Raltegravir may enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: May decrease the serum concentration of Raltegravir. Raltegravir may decrease the serum concentration of Fosamprenavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Raltegravir may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Raltegravir. Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the serum concentration of Raltegravir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifabutin: May decrease the serum concentration of Raltegravir. Specifically, minimum serum concentrations (Cmin) may be reduced.  Total raltegravir exposure (i.e., AUC) may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Raltegravir. Management: Increase raltegravir dose to 800 mg twice daily (adult dose) when used concomitantly with rifampin. Concurrent use of rifampin with once-daily raltegravir (Isentress HD) is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May increase the serum concentration of Raltegravir. Rifapentine may decrease the serum concentration of Raltegravir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May decrease the serum concentration of Raltegravir. Management: Concurrent use of tipranavir/ritonavir with once-daily raltegravir (Isentress HD) is not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Raltegravir may enhance the myopathic (rhabdomyolysis) effect of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374906\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Variable absorption depending upon meal type (low- vs high-fat meal) and dosage form. Management: Raltegravir was administered without regard to meals in clinical trials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374889\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Raltegravir has high transfer across the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy); however, maternal antiretroviral medication should not be withheld due to concerns of preterm birth. Information related to stillbirth, low birth weight, and small for gestational age infants is limited. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines consider raltegravir to be the preferred integrase inhibitor for initial use in antiretroviral-naive pregnant patients and is useful when drug interactions with protease inhibitors are a concern. Because of its ability to rapidly suppress viral load, raltegravir may be useful in women who present late in pregnancy with high viral loads. Dose adjustments are not required in pregnant women; however, once daily dosing is not recommended until more data is available. Reversible elevation of liver enzymes occurred in a patient who initiated raltegravir late in pregnancy; monitor liver enzymes if used during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. When HIV is diagnosed during pregnancy in a female who has never received antiretroviral therapy, ART should begin as soon as possible after diagnosis. Females who become pregnant on a stable ART regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in nonpregnant adults; ART should be continued postpartum for all females living with HIV.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6771727\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The absolute CD4 cell count is currently recommended to monitor immune status in children of all ages; CD4 percentage can be used as an alternative in children &lt;5 years of age. This recommendation is based on the use of absolute CD4 cell counts in the current pediatric HIV infection stage classification and as thresholds for urgency of initiation of antiretroviral treatment (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Prior to initiation of therapy: Genotypic resistance testing, CD4 and viral load (every 3 to 4 months), CBC with differential, LFTs, BUN, creatinine, electrolytes, glucose, urinalysis (every 6 to 12 months), and assessment of readiness for adherence with medication regimen. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, urinalysis (at initiation), BUN, creatinine, albumin, total protein, lipid panel (at initiation), CD4, and viral load. After 1 to 2 weeks of therapy: Signs of medication toxicity and adherence. After 2 to 4 weeks of therapy: CBC with differential, viral load, signs of medication toxicity, and adherence; then every 3 to 4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, viral load, signs of medication toxicity, and adherence. Every 6 to 12 months: Lipid panel and urinalysis. CD4 monitoring frequency may be decreased to every 6 to 12 months in children who are adherent to therapy if the value is well above the threshold for opportunistic infections, viral suppression is sustained, and the clinical status is stable for more than 2 to 3 years. In patients with known or suspected complex drug resistance patterns, phenotypic resistance testing (usually in addition to genotypic resistance testing) should be performed (HHS [pediatric] 2017). Monitor for growth and development, signs of HIV-specific physical conditions, HIV disease progression, opportunistic infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374909\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Incorporation of viral DNA into the host cell&rsquo;s genome is required to produce a self-replicating provirus and propagation of infectious virion particles. The viral cDNA strand produced by reverse transcriptase is subsequently processed and inserted into the human genome by the enzyme HIV-1 integrase (encoded by the pol gene of HIV). Raltegravir inhibits the catalytic activity of integrase, thus preventing integration of the proviral gene into human DNA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5374911\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> The pharmacokinetic profile of raltegravir in children was similar to that observed in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Film-coated tablet (400 mg formulation): AUC increased twofold with high-fat meal; Chewable tablet: AUC decreased by ~6% with high-fat meal (not clinically significant); Oral suspension: The effect of food was not studied</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~83%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic glucuronidation mediated by UGT1A1</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 600 mg film-coated tablet, chewable tablet, and oral suspension have higher bioavailability compared to 400 mg film-coated tablet; dosage forms are not interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Film-coated tablet (400 mg formulation): ~3 hours; film-coated tablet (600 mg formulation): ~1.5 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~51%, as unchanged drug); urine (~32%; 9% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50723812\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">At birth, the enzyme responsible for the metabolism of raltegravir is low and increases over first the 4 to 6 weeks of life (HHS [pediatric 2017]). In neonates &lt;4 weeks of age, raltegravir competes with bilirubin for albumin protein-binding sites and may increase unconjugated bilirubin concentrations; however, in vitro data suggest that this effect is unlikely to be significant at typical serum concentration (HHS [perinatal 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5552127\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Isentress Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $112.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $450.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Isentress Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $450.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Isentress HD Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (60): $1,800.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Isentress Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (60): $1,800.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6875348\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Isentress (AE, AR, AT, AU, BB, BE, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, ET, FR, GB, GR, GT, HK, HN, HR, IE, IL, IS, IT, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PL, PT, QA, RO, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, ZW);</li>\n      <li>Isentress HD (BB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. <i>Lancet</i>. 2007;369(9569):1261-1269.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/17434401/pubmed\" target=\"_blank\" id=\"17434401\">17434401</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, Department of Health and Human Services. July 14, 2016. Available at <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a> Accessed December 10, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. April 2017. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Accessed July 17, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV &minus; United States, 2016. Available at <a href=\"https://stacks.cdc.gov/view/cdc/38856\" target=\"_blank\">https://stacks.cdc.gov/view/cdc/38856</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. <i>Drug Metab Dispos</i>. 2007;35(9):1657-1663.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/17591678/pubmed\" target=\"_blank\" id=\"17591678\">17591678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-na&iuml;ve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. <i>Lancet</i>. 2009;374(9692):796-806.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/19647866/pubmed\" target=\"_blank\" id=\"19647866\">19647866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nachman S, Acosta E, Zheng N, et al. Interim results from IMPAACT P1066: raltegravir (RAL) oral chewable tablet (CT) formulation in children 2-5 years. 18th Conference on Retroviruses and Opportunistic Infections (CROI). 2011 [Poster abstract 715 from 2011 CROI Conference].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nair V, Chi G. HIV integrase inhibitors as therapeutic agents in AIDS. <i>Rev Med Virol</i>. 2007;17(4):277-295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/17503547/pubmed\" target=\"_blank\" id=\"17503547\">17503547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry ME, Almaani N, Desai N, et al, &ldquo;Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.&rdquo; <i>Int J STD AIDS</i>, 2013 Aug;24(8):639-642. doi: 10.1177/0956462413481528. Epub 2013 Jul 15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/19647866/pubmed\" target=\"_blank\" id=\"19647866\">19647866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php. Last modified December 2013. Accessed December 30, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. <i>Lancet</i>. 2014;384(9958):1942-1951.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/25103176/pubmed\" target=\"_blank\" id=\"25103176\">25103176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). <i>AIDS</i>. 2011;25(17):2113-2122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/21857490/pubmed\" target=\"_blank\" id=\"21857490\">21857490</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 89430 Version 118.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F5374882\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5937103\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F6771674\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F50713372\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F6771726\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F5374928\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F5374884\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20326223\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F5374908\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6771675\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25708058\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5374899\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5374893\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5374894\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299978\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5374903\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F5374906\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5374889\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6771727\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5374909\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F5374911\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F50723812\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5552127\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6875348\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/89430|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">Raltegravir: Drug information</a></li><li><a href=\"topic.htm?path=raltegravir-patient-drug-information\" class=\"drug drug_patient\">Raltegravir: Patient drug information</a></li></ul></div></div>","javascript":null}